Senseonics Holdings (NASDAQ: SENS) has announced the European launch of the world’s first and only one-year implantable continuous glucose monitoring (CGM) system—Eversense 365—now available to patients with Type 1 and Type 2 diabetes in Sweden with launches in Germany, Spain, and Italy to follow as part of a phased roll out.
According to Senseonics, Eversense products are the only long-term CGM systems available with just one sensor that rests comfortably under the skin for a full year. Traditional CGMs last approximately 10 to 15 days.
In a statement, Tim Goodnow, PhD, president and CEO of Senseonics, commented, “This launch of Eversense 365 is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transition to an end-to-end commercial organization this year. Building on demonstrable commercial momentum in the U.S., European expansion is a key part of our Eversense 365 growth strategy, increasing our total addressable market by over 30 million patients.”
